Gough A, Abraha H, Li F, et al: Measurement of markers of osteoclast and osteoblast activity in patients with acute and chronic diabetic Charcot neuroarthropathy. .Diabet Med14::527. ,1997. .9223389)| false
Hanft JR, Goggin JP, Landsman A, et al: The role of combined magnetic field bone growth stimulation as an adjunct in the treatment of neuroarthropathy/Charcot joint: an expanded pilot study. .J Foot Ankle Surg37::510. ,1998. .
Hanft JR, Goggin JP, Landsman A, et al: The role of combined magnetic field bone growth stimulation as an adjunct in the treatment of neuroarthropathy/Charcot joint: an expanded pilot study. .J Foot Ankle Surg37::510. ,1998. .9879046)| false
Evaluation and Treatment of Stage 0 Charcot’s Neuroarthropathy of the Foot and Ankle
Gerard V. Yu
Gerard V. YuDiplomate, American Board of Podiatric Surgery; Fellow, American College of Foot and Ankle Surgeons; Director of Podiatric Medical Education and Residency Training, St Vincent Charity Hospital, Cleveland, OH; Faculty Member, The Podiatry Institute, Tucker, GA. Mailing address: 23823 Lorain Rd, Ste 280, North Olmstead, OH 44070.
Charcot’s neuroarthropathy is a relatively common disease in patients with diabetic neuropathy. If unrecognized or left untreated, Charcot’s neuroarthropathy can result in a severely misshapen and unstable foot and ankle. Ulceration, soft-tissue infection, and osteomyelitis frequently ensue, and partial or complete amputation of the foot is not uncommon. A high index of suspicion and proper interpretation of clinical and diagnostic findings are essential to establish a timely and accurate diagnosis and to institute appropriate treatment. The pathogenesis of neuroarthropathy is reviewed and diagnosis and treatment of the stage 0 diabetic Charcot foot are presented. (J Am Podiatr Med Assoc 92(4): 210-220, 2002)